SCIENTIFIC BACKGROUND

GBA

SCIENTIFIC BACKGROUND

Gaucher disease is an autosomal recessive disorder of glycosphingolipid catabolism caused by reduced or absent activity of the lysosomal enzyme β-glucocerebrosidase (GBA). Pathogenic variants in the GBA gene are causative. The enzyme defect leads to progressive systemic accumulation of glucocerebroside (glucosylceramide) or glucosylsphingosine predominantly in the lysosomes of macrophages. With increasing storage, the macrophages increase in size and become so-called Gaucher cells, which can be detected predominantly in the spleen, liver, and bone marrow and are characteristic of the clinical appearance.

 

In Gaucher disease, a differentiation is made between the non-neuronopathic and neuronopathic forms of the disease. The non-neuronopathic form (classic type I) shows a chronic course with hepatosplenomegaly, hematological changes, and bone involvement without neurological symptoms. This type is the most common, accounting for 95% of cases, although disease onset and clinical expression are variable. The neuronopathic form can be acute or chronic. The acute neuronopathic form (classic type II) is characterized by severe neurologic complications that usually lead to death within the first two years of life. The chronic neuronopathic type (classic type III) differentiates from the acute form by a later onset of the disease and less progression, and is usually associated with marked hepatosplenomegaly and severe bone involvement.

 

Two treatment strategies are available for the management of Gaucher disease. Enzyme replacement therapy involves intravenous administration of the recombinant enzyme, which degrades glucocerebrosides stored in Gaucher cells. Alternatively, substrate reduction therapy is available, which reduces the rate of synthesis of glucocerebroside, thereby preventing its accumulation. Substrate reduction therapy with the active ingredient eliglustat is designed for the long-term treatment of adult patients with Gaucher disease type I. The efficacy of eliglustat depends on the CYP2D6 metabolizer status of the patient. Therefore, determination of CYP2D6 metabolizer type should be performed prior to initiation of therapy (Cerdelga summary of product characteristics).

 

Direct measurement of β-glucocerebrosidase activity in leukocytes should be performed prior to molecular genetic testing of the GBA gene (ACMG Practice Guideline, 2011).

 

References

Scott 2015, Drugs 75:1669 / Nagral 2014, J Clin Exp Hepatol 4:37 / Cassinerio et al. 2013, Eur J Intern Med. 25:117 / Grabowski 2012, Hematology Am Soc Hematol Educ Program 13 / Karaca et al. 2012, J Pediatr Endocr Met 25:957 / ACMG Practice Guideline, Wang et al. 2011, Genetics IN Medicine 13:457 / Bodamer et Hung 2010, Wien Med Wochenschr 160:600

GENES

GBA

ASSOCIATED TESTS

How to order

LATEST ARTICLES

Cancer is a group of genetic diseases that can develop almost anywhere in the body. Many people in the world are affected by cancer every year. Follo...

Read more

Aiming to evaluate the role of chromosomal aneuploidy in pregnancy loss, a 2023 study 35 years in the making evaluated the genomic landscape of first...

Read more

Cancer is a complex genetic disease that affects millions of people in the world. It is one of the leading causes of death worldwide, with about ten ...

Read more

Researchers created a detailed map of the placenta during labor. By studying how maternal and fetal cells communicate, they discovered signals in the...

Read more

A recent paper published in Nature Medicine (1) aimed to identify genes and genomic biomarkers which can better predict outcomes and personalized the...

Read more

In honor of the international day of women and girls in science, we interviewed one of our very own, Dr. Evelina Papaioannou. Dr. Evelina Pa...

Read more

Aneuploidies, such as translocations, whole or segmental chromosomal duplications, and deletions, are examples of chromosomal abnormalities that are ...

Read more

Here you can read the winning essays from the first, annual DNA essay competition on the subject of "How unfolding the DNA code can help with precisi...

Read more

Introduction Our voices are as unique as our fingerprints! Although there are people whose voices might sound alike, there are no two voices exact...

Read more

Not everyone likes winter. For people who do not enjoy the cold weather, or having to put on a thick coat to go outside, a winter can be a source of ...

Read more